lifitegrast Xiidra
Selected indexed studies
- Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). (Ophthalmology, 2017) [PMID:28079022]
- Targeting integrin pathways: mechanisms and advances in therapy. (Signal Transduct Target Ther, 2023) [PMID:36588107]
- Lifitegrast. (, 2006) [PMID:29999933]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. (2020) pubmed
- Lifitegrast. (2006) pubmed
- Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). (2017) pubmed
- Lifitegrast for the treatment of dry eye disease in adults. (2017) pubmed
- Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease. (2017) pubmed
- Quintessence of currently approved and upcoming treatments for dry eye disease. (2025) pubmed
- Targeting integrin pathways: mechanisms and advances in therapy. (2023) pubmed
- Lifitegrast (Xiidra) for Dry Eye Disease. (2017) pubmed
- Lifitegrast (Xiidra) for dry eye disease. (2016) pubmed
- Practical Synthesis of 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid-Key Intermediate of Lifitegrast (Xiidra). (2023) pubmed